MD Anderson and Xencor Enter Strategic Collaboration to Develop Novel T Cell-Engaging Bispecific Antibodies for Potential Treatment of Patients With Cancer
January 07, 2021
January 07, 2021
HOUSTON, Texas, Jan. 7 (TNSRes) -- The University of Texas's MD Anderson Cancer Center issued the following news release on Jan. 6:
The University of Texas MD Anderson Cancer Center and Xencor, Inc. today announced a strategic research collaboration and commercialization agreement to develop novel CD3 bispecific antibody therapeutics for the potential treatment of patients with cancer.
This collaboration joins Xencor's innovative XmAb(R) technology and protein . . .
The University of Texas MD Anderson Cancer Center and Xencor, Inc. today announced a strategic research collaboration and commercialization agreement to develop novel CD3 bispecific antibody therapeutics for the potential treatment of patients with cancer.
This collaboration joins Xencor's innovative XmAb(R) technology and protein . . .